MedTrace Logo

A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

NCT03499704 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 26.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Pioglitazone + Alogliptin

Pioglitazone and Alogliptin FDC tablets

DRUG

Alogliptin

Alogliptin tablets.

DRUG

Metformin

Metformin tablets.

DRUG

Dapagliflozin

Dapagliflozin tablets.

Sponsors & Collaborators

  • Celltrion Pharm, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Team · Celltrionpharm Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-11
Primary Completion
2024-01-02
Completion
2024-01-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03499704 on ClinicalTrials.gov